$ASPI Cashflow Statement | Understand Stock

$ASPI

$2.02 +$0.07 (3.86%) Close

$ASPI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Cash flows from Operating activities
Net income (loss)
Adjustments to reconcile net loss to cash used in operating activities:
Foreign exchange transaction gain from intercompany
Foreign exchange transaction loss from intercompany
Depreciation
Non cash in-process research and development
Depreciation and amortization
Allowance for credit losses
Loss on disposal of property and equipment
Non cash interest income on note receivable
Stock-based compensation
Issuance of common stock to founders
Issuance of warrant to purchase common stock
Change in right-of-use lease asset
Issuance of common stock to consultant
Convertible note payable for non-cash issuance costs
Shares issued for non-cash consultant expense
Change in fair value of share liability
Change in fair value of convertible notes payable
Change in fair value of investments
Change in right-of-use lease assets
Non-cash lease income
Change in deferred tax assets, net
Change in deferred taxes
Changes in operating assets and liabilities, net of acquisition amounts:
Accounts receivable
Receivable from noncontrolling interest
Inventories
Prepaid expenses and other current assets
Other noncurrent assets
Accounts payable
Accrued expenses
Deferred revenue
Operating lease liability
Tax liability current
Other current liabilities
Net cash used in operating activities

Cash flows from investing activities
Purchases of property and equipment
Purchases of short-term investments
Cash advance paid for property and equipment
Purchase of equity investments
Principal collections from lease receivable
Cash advance in exchanges for note receivable
Cash received for acquisition of businesses, net of cash paid
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of common stock
Payment of common stock issuance costs
Proceeds from issuance of notes payable
Payment of deferred issuance costs
Proceeds from exercise of warrants
Proceeds from exercise of options
Due to related parties
Contributions from noncontrolling interest
Proceeds from noncontrolling interest in VIE
Proceeds from collection of receivable from noncontrolling interest in VIE
Distribution to noncontrolling interest in VIE
Proceeds from issuance of convertible notes payable
Proceeds from issuance of debt
Payments of notes payable
Payment of bank loan
Payments of prinicipal portion of debt
Payment of principal portion of finance leases
Net cash provided by financing activities

Net change in cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents
Cash and cash equivalents - beginning of year
Cash and cash equivalents - end of year
Share liability for non-cash issuance costs
Purchase of property and equipment included in accounts payable
Supplemental cash flow information:
Cash paid for taxes
Supplemental disclosures of non-cash investing and financing activities:
Derecognition of asset as a result of sales type lease
Lease receivable
Purchase of property and equipment included in accounts payable
Right-of-use assets obtained in exchange for operating lease liability
Right-of-use assets obtained in exchange for financing lease liability
Seller financed portion of investment in East Coast Nuclear Pharmacy
Unpaid financing fees
Deemed dividend on inducement warrant
Purchase of property and equipment with bank loans
Board fees settled with common stock
Commission fee settled with common stock warrant
Issuance of common stock in lieu of commissions
Settlement of liabilities with related party
Share liability for non-cash issuance costs
Seller financed portion of investment in PET Labs Pharmaceuticals

Comments